What is Leerink Partnrs’ Forecast for VYGR Q1 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Voyager Therapeutics in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo forecasts that the company will post earnings per share of ($0.17) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS and Q4 2025 earnings at ($0.17) EPS.

VYGR has been the topic of a number of other reports. Wedbush assumed coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald started coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $5.73 price target on the stock. Finally, Citigroup assumed coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $15.97.

Voyager Therapeutics Trading Up 1.8 %

Shares of NASDAQ:VYGR opened at $5.53 on Friday. The company has a market capitalization of $302.10 million, a PE ratio of 7.79 and a beta of 0.93. Voyager Therapeutics has a 12-month low of $4.99 and a 12-month high of $10.66. The business has a 50 day moving average of $5.82 and a two-hundred day moving average of $6.67.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the prior year, the business earned ($0.59) earnings per share.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares during the period. Intech Investment Management LLC purchased a new stake in Voyager Therapeutics in the third quarter valued at $74,000. Hsbc Holdings PLC acquired a new position in shares of Voyager Therapeutics in the 2nd quarter valued at $128,000. SG Americas Securities LLC grew its holdings in shares of Voyager Therapeutics by 86.7% during the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock worth $131,000 after purchasing an additional 10,704 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth about $216,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 10,778 shares of company stock worth $58,548 over the last ninety days. Corporate insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.